This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Clariant board approves management’s updated strategy, claims wide investor support

( November 24, 2017, 16:00 GMT | Official Statement) -- Clariant, the Swiss chemical maker fending off an activist investor, said its board had approved management’s plans to update its strategy following a failed merger with US rival Huntsman. The deal was scrapped under pressure from White Tale Holdings, which holds more than 20 percent of Clariant’s shares and is pressing for board seats and an independent strategic review. Management’s updated strategy would “further enhance growth and value creation” and had the backing of Clariant’s Süd-Chemie legacy shareholders and “the majority of institutional shareholders,” the company said.Full statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login